There are few empirical data to inform the use and regulation of direct-to-consumer (DTC) genome-wide disease risk tests. The Scripps Genomic Health Initiative is a prospective longitudinal cohort study that aims to determine the psychological, behavioral, and clinical impacts of genomic testing for common disease susceptibility.  Our findings at one-year follow-up indicate that over a third of 2240 DTC genomic test recipients shared their results with their physician, and that this sharing was associated with higher rates of health screening test completion. Genomic testing was not associated with psychological risks, and most participants perceived the test to be of high personal utility. (By Dr. Cinnamon Bloss, http://jmg.bmj.com/content/early/2013/04/03/jmedgenet-2012-101207 )